ImmunoGen, Inc. develops targeted anticancer therapeutics. The company’s proprietary Targeted Antibody Payload (TAP) technology and strong antibody expertise form the basis for our development of our own products as well as of our partnerships with other companies.
Ten TAP compounds are now in the clinic, of which three are wholly owned by the Company. The most advanced compound using ImmunoGen’s TAP technology,?ado-trastuzumab emtansine (Kadcyla?), has been approved for marketing in the US and?Switzerland, and is undergoing regulatory review in the?European Union?and?Japan. ado-trastuzumab emtansine?is being commercialized in the US by?Genentech, a member of the Roche Group.
830 Winter Street
Waltham, MA 02451-1477
U.S.A
Web: ImmunoGen, Inc.
Advertisement #5
